ArticleThe journal of headache and pain2024
Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan.
Article in The journal of headache and pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Global trends in migraine and anxiety over the past 10 years: a bibliometric analysis.Frontiers in neurology · 2024Pooled it
- A Phase 1, Randomized, Placebo-Controlled, Multiple-Dose, Double-Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals.Clinical pharmacology in drug development · 2026Trial
- Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.The journal of headache and pain · 2026Trial
- Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.The journal of headache and pain · 2025Trial
- Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.Headache · 2025Trial
- Trial
- Characteristics and Treatment Patterns in People with Burden of Migraine: A Subgroup Analysis of the OVERCOME Japan 2nd Study.Pain and therapy · 2026Article
- Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.Drugs - real world outcomes · 2026Article
- Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan.Neurology and therapy · 2026Article
- Real-World Characteristics and Treatment Patterns of Calcitonin Gene-Related Peptide Monoclonal Antibody Users: a Japanese Claims Database-Based Study.Pain and therapy · 2026Article
- Clinical and social burden of migraine in Japanese males: a cross-sectional comparison with females without menstrual migraine.The journal of headache and pain · 2026Article
- Current landscape of migraine care with expert consensus from East Asia.The journal of headache and pain · 2026Review
- Migraine and the Excessive Dispensation of Triptans: A Real-World Evidence Study of Colombian Patients.Revista de neurologia · 2026Article
- Prognostic impact of the timing of antihypertensive medication initiation for hypertension detected at health screening on primary prevention of adverse cardiovascular events: Age-stratified real-world data analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Observational
- The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.The journal of headache and pain · 2025Observational
- Real-world use of over-the-counter medications by patients with migraine in Japan: results from the OVERCOME (Japan) 2nd study.The journal of headache and pain · 2025Observational
- Epidemiology of clinically significant migraine in Israel: a retrospective database study.The journal of headache and pain · 2025Article
- Prevalence, Treatment, and Unmet Needs of Migraine in the Middle East: A Systematic Review.Pain and therapy · 2025Review
- The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study.Neurology and therapy · 2025Article
- Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription.Therapeutic advances in neurological disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical characteristics and treatment practice of patients with migraine in Japan in real-world setting have not been fully investigated. We conducted a retrospective cohort study using claims database to understand the clinical practice of migraine in recent years and to characterize patients potentially not managed well by current treatment options.
methodsOur study used data from the large claims database maintained by JMDC Inc. Patients with diagnosis of headache or migraine between January 1, 2018, and July 31, 2022, were defined as the headache cohort, and those with migraine diagnosis and prescription of migraine treatments among the headache cohort were included in the migraine cohort. In the headache cohort, characteristics of medical facilities and status of imaging tests to distinguish secondary headache were examined. Treatment patterns and characteristics of patients potentially not managed well by acute/preventive treatment were described in migraine cohort.
resultsIn the headache cohort, 989,514 patients were included with 57.0% females and mean age of 40.3 years; 77.0% patients visited clinics (with ≤ 19 bed capacities) for their primary diagnosis, and 30.3% patients underwent imaging tests (computed tomography and/or magnetic resonance imaging). In the migraine cohort, 165,339 patients were included with 65.0% females and mean age of 38.8 years. In the migraine cohort, 95.6% received acute treatment while 20.8% received preventive treatment. Acetaminophen/non-steroidal anti-inflammatory drugs were most common (54.8%) as the initial prescription for migraine treatment followed by triptan (51.4%). First treatment prescription included preventive treatment in 15.6%, while the proportion increased to 82.2% in the fourth treatment prescription. Among patients with more than 12 months of follow-up, 3.7% had prescription patterns suggestive of risk of medication-overuse headache, and these patients were characterized by a higher percentage of females and a higher prevalence of comorbidities.
conclusionsThis study revealed that approximately one-fifth of the patients with migraine visiting medical facilities use preventive drugs. The presence of potential patients at risk of medication-overuse headache and the role of clinics in migraine treatment were also described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.